Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer

Cardiol Clin. 2019 Nov;37(4):505-523. doi: 10.1016/j.ccl.2019.07.015.

Abstract

Cardiovascular effects of cancer therapies are of concern. Prediction, diagnosis, and management of cardiotoxicity is a challenge. Cardiovascular biomarkers are being studied in relationship to cancer therapy, showing promise in detection and prevention of cardiotoxicity. We summarize the use of biomarkers in cardio-oncology and presents recommendations for their use. Troponins and natriuretic peptides are the most commonly used biomarkers. High-quality evidence supporting their use is lacking. Biomarkers can be incorporated into a detection strategy for cardiotoxicity. Large, well-powered studies are needed to delineate care strategies using biomarkers in the prediction and management of the cardiovascular effects of cancer therapy.

Keywords: Anthracycline; Biomarkers; Brain natriuretic peptide; Cancer; Cardiotoxicity; Chemotherapy; Trastuzumab; Troponin.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Cardiotoxicity
  • Cardiovascular Diseases* / blood
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Combined Modality Therapy / adverse effects
  • Global Health
  • Humans
  • Incidence
  • Neoplasms* / complications
  • Neoplasms* / metabolism
  • Neoplasms* / therapy
  • Risk Assessment / methods*

Substances

  • Biomarkers, Tumor